Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys.

Summary: Antiretroviral nucleoside analogue drugs are a major constituent of highly active antiretroviral therapy (HAART). the most advanced form of treatment for HIV-1 infection. Currently, HAART combinations that include zidovudine (ZDV) and lamivudine (3TC) are highly effective in preventing HIV-1 vertical transmission; most children are born with no evident adverse clinical effects. However, ZDV is a moderately strong transplacental carcinogen in mice, and potential long-term consequences of fetal exposure to most HAART combinations remain unknown. To model human transplacental ZDV and 3TC exposures, experiments were performed in Erythrocebus patas monkeys given human-equivalent drug exposure protocols. Pregnant monkeys were dosed with either no drug (n = 2), 40.0 mg ZDV/d (about 6 mg/kg body weight/d) for the last 50% (10 weeks) of gestation (n = 3), or with the same regimen of ZDV plus 24.0 mg 3TC/d (about 3.6 mg/kg body weight/d) for the last 20% (4 weeks) of gestation (n = 3). Multiple fetal organs were examined at term for DNA incorporation of ZDV and 3TC using two separate radioimmunoassays (RIAs). Values for ZDV-DNA incorporation were similar in fetuses exposed to ZDV alone and those exposed to ZDV plus 3TC. Values for 3TC-DNA in fetal organs were greater than or equal to values for ZDV-DNA, indicating that the total DNA damage sustained by fetuses exposed to both drugs was at least double that observed in fetuses exposed to ZDV alone. Telomere shortening, determined by Southern blot with a telomeric probe, was observed in most organs of the three animals exposed in utero to ZDV plus 3TC. No telomere shortening was evident in the unexposed fetuses, and occasional telomere shortening was found in fetuses exposed to ZDV alone. Overall, these studies demonstrate that monkey fetuses exposed in utero to the combination ZDV plus 3TC sustain a higher level of drug-DNA incorporation and show evidence of more telomere damage than monkey fetuses exposed to ZDV alone.

[1]  M. Poirier,et al.  Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  W. Hauck,et al.  Prenatal zidovudine use and congenital anomalies in a medicaid population. , 2000 .

[3]  M. Poirier,et al.  Relationships between DNA incorporation, mutant frequency, and loss of heterozygosity at the TK locus in human lymphoblastoid cells exposed to 3'-azido-3'-deoxythymidine. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[4]  J. O’Neill,et al.  Genotoxicity of 3'-azido-3'-deoxythymidine in the human lymphoblastoid cell line, TK6: relationships between DNA incorporation, mutant frequency, and spectrum of deletion mutations in HPRT. , 1999, Mutation research.

[5]  S. Gortmaker,et al.  Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. , 1999, JAMA.

[6]  P. Harrigan,et al.  Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. , 1998, The Journal of infectious diseases.

[7]  J. Grassi,et al.  Development of a New Cartridge Radioimmunoassay for Determination of Intracellular Levels of Lamivudine Triphosphate in the Peripheral Blood Mononuclear Cells of Human Immunodeficiency Virus-Infected Patients , 1998, Antimicrobial Agents and Chemotherapy.

[8]  V. Pathak,et al.  Deoxyribonucleoside Triphosphate Pool Imbalances In Vivo Are Associated with an Increased Retroviral Mutation Rate , 1998, Journal of Virology.

[9]  D. Gomez,et al.  Irreversible telomere shortening by 3'-azido-2',3'-dideoxythymidine (AZT) treatment. , 1998, Biochemical and biophysical research communications.

[10]  L. Anderson,et al.  Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. , 1997, Journal of the National Cancer Institute.

[11]  S. Dertinger,et al.  Induction of micronuclei by low doses of azidothymidine (AZT). , 1996, Mutation research.

[12]  D. Gomez,et al.  Preferential incorporation of 3'-azido-2',3'-dideoxythymidine (azt) in telomeric sequences of cho cells. , 1995, International journal of oncology.

[13]  R. Gelber,et al.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.

[14]  I. Larripa,et al.  Genotoxic activity of azidothymidine (AZT) in in vitro systems. , 1994, Mutation research.

[15]  E. Blackburn,et al.  The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena. , 1994, Nucleic Acids Research.

[16]  F. Beland,et al.  Immunofluorescent localization and quantitation of 3'-azido-2',3'-dideoxythymidine (azt) incorporated into chromosomal DNA of human, hamster and mouse-cell lines. , 1994, International journal of oncology.

[17]  J. Sommadossi,et al.  Cellular pharmacology of 3'-azido-3'-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells. , 1989, Molecular pharmacology.